Differential effects of angiotensin II on cardiac cell proliferation and intramyocardial perivascular fibrosis in vivo

Circulation

Volumn 98, Issue 24, 1998, Pages 2765-2773

  McEwan, Pauline E ^a   Gray, Gillian A ^a   Sherry, Lorcan ^a   Webb, David J ^a   Kenyon, Christopher J ^a  

^a UNIVERSITY OF EDINBURGH   (United Kingdom)

Author keywords

Angiotensin; Cells; Receptors

Indexed keywords

ANGIOTENSIN; LOSARTAN;

ANIMAL CELL; ARTICLE; CELL INTERACTION; CELL PROLIFERATION; DRUG EFFECT; FIBROBLAST; HEART MUSCLE CELL; HEART MUSCLE FIBROSIS; HEART RIGHT ATRIUM; IN VIVO STUDY; NONHUMAN; PRIORITY JOURNAL; RAT; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; SMOOTH MUSCLE FIBER; VASCULAR RESISTANCE; VASCULAR SMOOTH MUSCLE;

EID: 0032534462     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.CIR.98.24.2765     Document Type: Article

References (46)

1. Dargie HJ, McMurray JJV, McDonagh TA. Heart failure: implications of the true size of the problem. J Intern Med. 1996;239:309-315.
2. Laragh JH. Renin angiotensin aldosterone system for blood pressure and electrolyte homeostasis and its involvement in hypertension, in congestive heart failure and in associated cardiovascular damage (myocardial infarction and stroke). J Hum Hypertens. 1995;9:385-390.
3. Heagerty AM, Bund SJ, Izzard AS. Long-term structural changes in human hypertensive vessels. Drugs Today. 1995;31:15-19.
4. Heagerty AM, Izzard SJ. Small artery changes in hypertension. J Hypertens. 1995;13:156-165.
5. Cohn JN. Structural basis for heart failure: ventricular remodeling and its pharmacological inhibition. Circulation. 1995;91:2504-2507.
6. Cooper RS, Simmons BE, Castaner A, Santhanam V, Ghali J, Mar M. Left ventricular hypertrophy is associated with worse survival, independent of ventricular function and number of coronary arteries severely narrowed. Am J Cardiol. 1990;65:441-445.
7. Pearlman ES, Weber KT, Janicki JS, Pietra G, Fishman AP. Muscle fiber orientation and connective tissue content in the hypertrophied human heart. Lab Invest. 1982;46:158-164.
8. Weber KT, Brilla CG. Pathological hypertrophy and cardiac interstitium: fibrosis and renin-angiotensin-aldosterone system. Circulation. 1991;83: 1849-1865.
9. Weber KT, Brilla CG, Janicki JS. Myocardial fibrosis: functional significance and regulatory factors. Cardiovasc Res. 1993;27:341-348.
10. Harada M, Itoh H, Nakagawa O, Ogawa Y, Miyamoto Y, Kuwahara K, Ogawa E, Igaki T, Yamashita J, Masuda I, Yoshimasa T, Tanaka I, Saito Y, Nakao K. Significance of ventricular myocytes and nonmyocyte interaction during cardiac hypertrophy: evidence for endothelin-1 as a paracrine hypertrophic factor from cardiac nonmyocytes. Circulation. 1997;96:3737-3744.
11. Bobik A, Campbell JH. Vascular derived growth factors: cell biology, pathophysiology and pharmacology. Pharmacol Rev. 1993;45:1-42.
12. Ko Y, Nickenig G, Wieczorek AJ, Vetter H, Sachinidis A. Synergistic action of angiotensin II, insulin-like growth factor-I and transforming growth factor beta on platelet-derived growth factor-BB, basic fibroblast growth factor and epidermal growth factor-induced DNA synthesis in vascular smooth muscle cells. Am J Hypertens. 1993;6:496-499.
13. Fujisaki H, Ito H, Hirata Y, Tanaka M, Hata M, Lin M, Adachi S, Akimoto H, Maramo F, Hiroe M. Natriuretic peptides inhibit angiotensin II-induced proliferation of rat cardiac fibroblasts by blocking endothelin-1 gene expression. J din Invest. 1995;96:1059-1065.
14. Silver MA, Pick R, Brilla CG, Jalil JE, Janicki JS, Weber KT. Reactive and reparative fibrosis in the hypertrophied rat left ventricle: two experimental models of myocardial fibrosis. Cardiosc Res.. 1990;24: 741-747.
15. Weber KT, Sun Y, Guarda E. Structural remodeling in hypertensive heart disease and the role of hormones. Hypertension. 1994;23:869-877.
16. Brilla CG, Janicki JS, Weber KT. Cardioreparative effects of lisinopril in rats with genetic hypertension and left ventricular hypertrophy. Circulation. 1991;83:1771-1779.
17. Campbell SE, Janicki JS, Weber KT. Temporal differences in fibroblast proliferation and phenotype expression in response to chronic administration of angiotensin II or aldosterone. J Mol Cell Cardiol. 1995;27: 1545-1560.
18. Campbell SE, Janicki JS, Matsubara BB, Weber KT, Myocardial fibrosis in the rat with mineralocorticoid excess: prevention of scarring by amiloride. Am J Hypertens. 1993;6:487-495.
19. Weber KT, Brilla CG. Pathological hypertrophy and cardiac interstitium. Circulation. 1991;83:1849-1865.
20. Daeman MJAP, Lombardi DM, Bosman FT, Schwartz, SM. Angiotensin II induces smooth muscle cell proliferation in the normal and injured rat arterial wall. Circ Res. 1991;68:450-456.
21. Schorb W, Booz D, Dostal M, Conrad MK, Chang KC, Baker KM. Angiotensin II is mitogenic in neonatal rat cardiac fibroblasts. Circ Res. 1993;72:1245-1254.
22. Makita S, Nakamura M, Yoshida H, Hiramori K. Effect of angiotensin II receptor blocker on angiotensin II-stimulated DNA synthesis of cultured human aortic smooth muscle cells. Life Sci. 1995;20:PL383-PL388.
23. Stoll M, Steckelings M, Paul M, Bottari S, Metzger R, Unger T. The angiotensin AT-2 receptor mediates inhibition of cell proliferation in coronary endothelial cells. J Clin Invest. 1995;95:651-657.
24. Sawamura I, Hazama F, Kinoshita M. Histological and histometrical study of myocardial fibrosis in spontaneously hypertensive rats of the stroke-prone strain. Jpn Circ J. 1990;54:1274-1282.
25. Sugihara N, Genda A, Shimizu M, Suematu T, Kita Y, Horita Y, Takeda R. Quantitation of myocardial fibrosis and its relation to function in essential hypertension and hypertrophic cardiomyopathy. Clin Cardiol. 1988;11:771-778.
26. Sun Y, Ramires FJA, Weber KT. Fibrosis of atria and great vessels in response to angiotensin II or aldosterone infusion. Cardiovasc Res. 1997; 35:138-147.
27. Brilla CG, Pick R, Tan LB, Janicki JS, Weber KT. Remodeling of the rat right ventricle and left ventricle in experimental hypertension. Circ Res. 1990;67:1355-1364.
28. Griffin SA, Brown WCB, MacPherson F, McGrath JC, Wilson VG, Korsgaard N, Mulvaney MJ, Lever AF. Angiotensin II causes vascular hypertrophy in part by a non-pressor mechanism. Hypertension. 1991;17: 626-635.
29. Gratzner HG. Monoclonal antibody to 5′-bromo- and 5′-iododeoxyuridine: a new reagent for detection of DNA replication. Science. 1982;218:474-480.
30. Verhofstad AAJ. Kinetics of adrenal medullary cells. J Anat. 1993;183: 315-326.
31. Kenyan CJ, McEwan PE, Holmes M. Long term treatment with 5-bromo2′-deoxyuridine does not affect the control of adrenocortical function. J Endocrinol. 1998;156:P2. Abstract.
32. Morton JJ, Beattie EC, MacPherson F. Angiotensin II receptor antagonist losartan has persistent effects on blood pressure in the young spontaneously hypertensive rat: lack of relation to vascular structure. J Vasc Res. 1992;29:264-269.
33. Evans AL, Brown W, Kenyon CJ, Maxted KJ, Smith DC. An improved system for measuring blood pressure in the conscious rat. Med Biol Eng Comput. 1994;32:101-102.
34. McEwan PE, Lindop G, Kenyon CJ. Control of cell proliferation in the rat adrenal gland in vivo by the renin-angiotensin system. Am J Physiol. 1996;271:E192-E198.
35. Barker S, Marchant W, Ho MM, Puddefoot JR, Hinson JP, Clark AJL, Vinson GP. A monoclonal antibody to a conserved sequence in the extracellular domain recognises the angiotensin II AT 1 receptor in mammalian tissues. J Mol Endocrinol. 1993;11:241-245.
36. Millar JA, Leckie BJ, Morton JJ. A micro-assay for active and total renin concentration in human plasma based on antibody trapping, Clin Chim Acta. 1980;101:5-15.
37. Malendowicz LK, Rebuffat P, Andreis PG, Nussdorfer GG, Novak M. Different mechanisms mediate the in vivo aldosterone and corticosterone responses to 5-bromo-2′-deoxyuridine in rats. Exp Clin Endocrinol Diabetes. 1997;105:277-281.
38. Sun Y, Ratajska A, Zhou G, Weber KT. Angiotensin converting enzyme and myocardial fibrosis in the rat receiving angiotensin II or aldosterone. J Lab Clin Med. 1993;122:395-403.
39. Bourgeois R, Laporte S, Escher E. The myoprolilerative response to vascular smooth muscle after injury is angiotensin II mediated through the ATI receptor. FASEB J. 1993;7:A47. Abstract.
40. Sun Y, Weber KT. Angiotensin converting enzyme and myofibroblasts during tissue repair in the rat heart. J Mol Cell Cardiol. 1996;28:851-858.
41. Brilla CG, Maisch B, Zhou G, Weber KT. Hormonal regulation of cardiac fibroblast function. Eur Heart J. 1995;16:45-50.
42. Brilla CG, Zhou G, Matsubara L, Weber KT. Collagen metabolism in cultured adult cardiac fibroblasts; response to angiotensin and aldosterone. J Mol Cell Cardiol. 1994;26:809-820.
43. Nahmias C, Cazaubon SM, Briend-Sutren MM, Lazard D, Villageois P, Strosberg AD. Angiotensin II AT2 receptors are functionally coupled to protein tyrosine dephosphorylation in N1E-115 neurobiastoma cells. Biochem J. 1995;306:87-92.
44. Liakos P, Bourmeyster N, Defaye G, Chambaz EM, Bottari SP. Angiotensin II AT1 and AT2 receptors both inhibit bFGF-induced proliferation of bovine adrenocortical cells. Am J Physiol. 1997;273:C1324-C1334.
45. Radhakrishan R, Sim MK. Enhanced pressor response to angiotensin III in spontaneously hypertensive rats: effects of losartan. Eur J Pharmacol. 1994;259:87-90.
46. Hubner N, Kreutz R, Takakashi S, Ganten D, Lindpainter K. Altered angiotensinogen amino acid sequence and plasma angiotensin II in genetically hypertensive rats: a study on cause and effect. Hypertension. 1995;26:279-284.